Aphria Inc. has reached a worldwide licence agreement with Manna Molecular Science, LLC regarding the latter company’s state-of-the-art cannabis transdermal patches.
“Under the agreement, Manna grants Aphria exclusive preferred vendor status for a period of five years, and an exclusive licence to produce, market, distribute, promote and sell Manna patches containing cannabis oil as an active ingredient,” notes a statement from Leamington, Ont.-headquartered Aphria, a global cannabis company.
Developed by pharmaceutical scientists from Massachusetts Institute of Technology using state-of-the-art product design and research methods, the patch “works for all cannabinoids and is designed to work with high-quality, whole-plant cannabis extracts, which are printed on each patch with pharmaceutical quality,” the press release explains. “Each patch is latex- and allergen-free and delivers the dose automatically through the skin over the course of 12 hours,” it adds.
“Leveraging Manna’s established formulations, equipment and processes, Aphria will produce and sell patches containing cannabis oils for its established suite of medical and adult-use brands,” Aphria reports. Manna combines whole-plant cannabis extracts with innovative technology to evolve cannabis medicine for everyday life.
“As a company at the forefront of cannabis innovation, Manna Molecular Science will be an important strategic partner for Aphria. Like us, they are committed to making safe, high-quality cannabis products available to a wide array of global consumers,” comments Aphria president Jakob Ripshtein.
“Aphria gives Manna the reach to distribute the Manna patch at a global level and share our principles of excellence in product design and manufacturing with the world outside the U.S.,” adds Manna CEO Nial C. DeMena.